

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Prout Samantha</u> _____ (Last) (First) (Middle) <u>C/O AMICUS THERAPEUTICS, INC.</u> <u>3675 MARKET STREET</u> _____ (Street) <u>PHILADELPHIA PA 19104</u> _____ (City) (State) (Zip)		2. Issuer Name and Ticker or Trading Symbol <u>AMICUS THERAPEUTICS, INC. [FOLD]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Accounting Officer</u>
		3. Date of Earliest Transaction (Month/Day/Year) <u>08/09/2023</u>	
		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/09/2023		M		2,376	A	\$10.04	139,379	D	
Common Stock	08/09/2023		M		5,040	A	\$9.55	144,419	D	
Common Stock	08/09/2023		M		10,592	A	\$10.03	155,011	D	
Common Stock	08/09/2023		M		18,901	A	\$12.11	173,912	D	
Common Stock	08/09/2023		S		36,909	D	\$14.0056 ⁽¹⁾	137,003	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Options (right to buy)	\$10.04	08/09/2023		M			2,376	(2)	01/02/2029	Common Stock	2,376	\$0.00	0	D	
Stock Options (right to buy)	\$9.55	08/09/2023		M			5,040	(3)	01/02/2030	Common Stock	5,040	\$0.00	2,526	D	
Stock Options (right to buy)	\$10.03	08/09/2023		M			10,592	(4)	04/15/2030	Common Stock	10,592	\$0.00	3,176	D	
Stock Options (right to buy)	\$12.11	08/09/2023		M			18,901	(5)	01/14/2032	Common Stock	18,901	\$0.00	37,810	D	

Explanation of Responses:

- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$14.00 to \$14.10 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- All of these options were fully vested and exercisable as of the transaction date.
- As of August 9, 2023, 5,985 options were fully vested and exercisable and 1,581 remained unvested from this individual 2020 grant.
- As of August 9, 2023, 11,164 options were fully vested and exercisable and 2,604 remained unvested from this individual 2020 grant.
- As of August 9, 2023, 22,444 options were fully vested and exercisable and 34,267 remained unvested from this individual 2022 grant.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2023.

/s/ Christian Formica,
Attorney-in-Fact

08/11/2023

** Signature of Reporting Person

Date

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.